Everpar Advisors LLC Purchases Shares of 3,847 Danaher Co. (NYSE:DHR)

Everpar Advisors LLC purchased a new stake in Danaher Co. (NYSE:DHR) in the 4th quarter, according to its most recent filing with the SEC. The fund purchased 3,847 shares of the conglomerate’s stock, valued at approximately $890,000.

Other institutional investors also recently bought and sold shares of the company. Gryphon Financial Partners LLC increased its holdings in shares of Danaher by 19.1% during the 4th quarter. Gryphon Financial Partners LLC now owns 2,917 shares of the conglomerate’s stock worth $675,000 after buying an additional 468 shares during the last quarter. Patrick M Sweeney & Associates Inc. acquired a new stake in shares of Danaher during the 4th quarter worth $270,000. Palisade Asset Management LLC increased its holdings in shares of Danaher by 0.5% during the 4th quarter. Palisade Asset Management LLC now owns 24,880 shares of the conglomerate’s stock worth $5,756,000 after buying an additional 117 shares during the last quarter. Peddock Capital Advisors LLC increased its holdings in shares of Danaher by 3.2% during the 4th quarter. Peddock Capital Advisors LLC now owns 5,699 shares of the conglomerate’s stock worth $1,318,000 after buying an additional 176 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Danaher by 2.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 3,718,735 shares of the conglomerate’s stock worth $860,292,000 after buying an additional 95,440 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have recently commented on DHR. Citigroup upped their price objective on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. TD Cowen upped their price objective on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Barclays upped their price target on shares of Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 24th. Bank of America upped their price target on shares of Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 24th. Finally, Raymond James upped their price target on shares of Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. Six equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $267.31.

Insider Activity

In other news, Director Alan G. Spoon sold 708 shares of the firm’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total value of $172,454.64. Following the transaction, the director now directly owns 116,202 shares in the company, valued at approximately $28,304,483.16. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, Director Alan G. Spoon sold 708 shares of the stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total transaction of $172,454.64. Following the sale, the director now directly owns 116,202 shares in the company, valued at approximately $28,304,483.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Rainer Blair sold 47,175 shares of the business’s stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total value of $11,756,953.50. Following the transaction, the chief executive officer now owns 115,995 shares of the company’s stock, valued at approximately $28,908,273.90. The disclosure for this sale can be found here. In the last ninety days, insiders sold 103,984 shares of company stock worth $25,997,094. 10.90% of the stock is currently owned by insiders.

Danaher Stock Up 0.3 %

Shares of Danaher stock traded up $0.82 during trading hours on Wednesday, hitting $249.58. 1,471,344 shares of the company’s stock traded hands, compared to its average volume of 2,730,175. The stock has a 50 day simple moving average of $248.27 and a 200-day simple moving average of $233.19. The company has a quick ratio of 1.51, a current ratio of 1.85 and a debt-to-equity ratio of 0.31. The company has a market cap of $184.86 billion, a PE ratio of 42.30, a PEG ratio of 3.82 and a beta of 0.83. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $259.00.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.20. The company had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The company’s revenue was down 2.6% on a year-over-year basis. During the same period last year, the firm earned $2.36 earnings per share. Equities research analysts anticipate that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be given a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.43%. Danaher’s payout ratio is 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.